HEALTH● LOWSep 13 · Sep 13, 2026, 5:23 PM
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
Seeking Alpha Tech · global
A clinical trial shows Summit's drug, ivonescimab, reduced the risk of death by 27% compared to Keytruda in lung cancer patients. This represents a potentially important advancement in lung cancer treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH17m agoEbola scare in Adamawa: NCDC confirms negative testsVanguard NigeriaHEALTH26m agoEbola: Saudi Arabia suspends travel to Kenya, halts visa issuancePremium TimesHEALTH37m agoGroup seeks end to health workers’ absenteeism in PHCsPremium TimesHEALTH1h agoHealth authorities probe two suspected Ebola cases in northeast NigeriaAl Jazeera [en]